Maxwell Biosciences
Biotechnology ResearchTexas, United States11-50 Employees
Maxwell Biosciences, based in Austin, Texas, operates as a preclinical biotechnology company focused on developing anti-infective agents inspired by natural human antimicrobial peptides. It pursues a pipeline of low-molecular-weight drug candidates intended to defeat a broad range of pathogens, including SARS-CoV-2, other viruses, fungi, and bacteria, through a proprietary discovery platform. The company collaborates with large pharmaceutical partners to advance these candidates toward human testing and emphasizes a multi-asset, multi-target approach supported by a patent portfolio. Independent government-funded labs have reported virucidal activity of Maxwell's lead candidates against HSV-1 and SARS-CoV-2. Animal studies at Texas A&M and Baylor College of Medicine indicate tissue-safe toxicology and fungicidal action against lethal fungal infections, lending support to the platform's safety and breadth. In 2025 Maxwell expanded collaborations with U.S. government research programs, including cooperative agreements with the U.S. Army Institute of Surgical Research and the Naval Medical Research Command's NIDDL, as part of ongoing preclinical research and development.
1-888-653-2347 
support@leadiq.com 
